Norman Gitlin
Gastroenterology · Atlanta, GANPI 1669463543
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $120,212 of the $151,280 with a category attached, or 79.5%. 10 manufacturers reported payments, led by Gilead at 53.7% of the total. Among gastroenterology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $911.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$81K
- Madrigal Pharmaceuticals$32K
- Intercept Pharmaceuticals, Inc.$17K
- Ipsen Bioscience Inc.$10K
- Ipsen Biopharmaceuticals, Inc$5K
- Dova Pharmaceuticals$4K
- plus $1K from 4 others
Across 43 payments — averaging $5763.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$139K
- E.r. Squibb & Sons, L.L.C.$85K
- Intercept Pharma Europe Ltd.$15K
- Dova Pharmaceuticals$9K
- Intercept Pharmaceuticals, Inc.$198
- Novo Nordisk AS$121
What the payments were for
- Consulting fees$13,5139%
- Speaking & faculty fees$120,21279%
- Travel & lodging$13,5319%
- Food & beverage$4,0253%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 92 | $81,275 |
| Madrigal Pharmaceuticals | 39 | $32,131 |
| Intercept Pharmaceuticals, Inc. | 16 | $17,442 |
| Ipsen Bioscience Inc. | 1 | $9,690 |
| Ipsen Biopharmaceuticals, Inc | 3 | $4,911 |
| Dova Pharmaceuticals | 5 | $4,488 |
| Shionogi Inc | 1 | $750 |
| Vertex | 1 | $325 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $251 |
| Orphalan Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$151,280 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezdiffraResmetirom | 23 | $98,593 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 19 | $324 |
| Azathioprine | 11 | $189 |
| Pantoprazole Sodium | 20 | $176 |
| Famotidine | 12 | $102 |
| Furosemide | 17 | $70 |
| Lisinopril | 13 | $9 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Madrigal PharmaceuticalsRezdiffra | $32,131 | $98,59323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Atlanta
- Nitin GuptaAtlanta$1.1M
- Cynthia RudertAtlanta$720K
- Douglas WolfAtlanta$668K
- Kavita KongaraAtlanta$492K
- Girish AnandAtlanta$425K
- Roshan ShresthaAtlanta$317K
- Hetal KarsanAtlanta$314K
- Marc SonenshineAtlanta$201K
- Julia LiuAtlanta$163K
- Huiming HonAtlanta$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.